<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04240158</url>
  </required_header>
  <id_info>
    <org_study_id>C6463-102</org_study_id>
    <secondary_id>CY6463</secondary_id>
    <nct_id>NCT04240158</nct_id>
  </id_info>
  <brief_title>IW-6463 Safety Study in Healthy Elderly Subjects</brief_title>
  <official_title>Evaluating the Safety, Tolerability, and Pharmacodynamic Properties of IW-6463 in Healthy Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyclerion Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cyclerion Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, 2-way cross-over study in healthy&#xD;
      male and female elderly participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will receive up to a total of 30 daily doses of study drug (15 days of daily&#xD;
      IW-6463, only; 15 days of daily placebo, only) administered across two 15-day dosing periods&#xD;
      (Period 1 and Period 2). The dosing periods will be separated by a 27-day washout.&#xD;
      Participants will be randomized to a sequence of receiving IW-6463 for Period 1 and then&#xD;
      placebo for Period 2, or vice versa.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Some subjects could not complete the second crossover period due to COVID-19-related site&#xD;
    closure. The study was closed to allow analysis of all collected data.&#xD;
  </why_stopped>
  <start_date type="Actual">January 6, 2020</start_date>
  <completion_date type="Actual">May 22, 2020</completion_date>
  <primary_completion_date type="Actual">May 22, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Cerebral Blood Flow (CBF) at Day 15</measure>
    <time_frame>Baseline, 15 days</time_frame>
    <description>Change from baseline in CBF as measured by magnetic resonance imaging (MRI) and arterial spin labeling (ASL) after administration of IW-6463 vs. placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to 42 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Other</condition>
  <arm_group>
    <arm_group_label>IW-6463</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IW-6463 tablets administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablets administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IW-6463</intervention_name>
    <description>IW-6463 Tablet</description>
    <arm_group_label>IW-6463</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Matching Placebo Tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is an ambulatory adult at least 65 years old at the screening visit&#xD;
&#xD;
          -  Subject is in good health and has no clinically significant findings on physical&#xD;
             examination&#xD;
&#xD;
          -  Female participants must be postmenopausal. A postmenopausal state is defined as no&#xD;
             menses for ≥12 consecutive months without an alternative medical cause. A high&#xD;
             follicle-stimulating hormone (FSH) level at screening (&gt;40 IU/L or mIU/mL) in the&#xD;
             postmenopausal range may be used to confirm a postmenopausal state.&#xD;
&#xD;
          -  Male participants who have not been surgically sterilized by vasectomy (conducted ≥60&#xD;
             days before the Screening Visit or confirmed via sperm analysis) must agree&#xD;
             contraceptive use per protocol&#xD;
&#xD;
          -  Men must also agree to not donate sperm throughout the study and for 3 months after&#xD;
             the final dose of study drug&#xD;
&#xD;
          -  Other inclusion criteria per protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any active or unstable clinically significant medical condition&#xD;
&#xD;
          -  Other exclusion criteria per protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chad Glasser, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Cyclerion Therapeutics, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geert Jan Groeneveld, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Human Drug Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Human Drug Research (CHDR)</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 21, 2020</study_first_submitted>
  <study_first_submitted_qc>January 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

